Legal Opinion
Genentech, Inc. v. Amgen Inc.
District Court, D. Delaware
Decided April 17, 2018No. Civ. No. 17–1407–GMS; Civ. No. 17–1471–GMSPublishedCited by 3 opinions
1Opinion of the Court
GREGORY M. SLEET, UNITED STATES DISTRICT JUDGE
In two related patent-infringement actions, plaintiffs Genentech, Inc. and City of Hope (collectively, "Genentech") have asserted multiple counts against defendant Amgen Inc. ("Amgen") based on Amgen's plans to commercialize Mvasi™, a biosimilar version of Genentech's Avastin ®. During the parties' so-called patent dance, Amgen made a statement pursuant to 42 U.S.C. § 262(l )(3)(B) that it did not intend to begin commercial marketing of Mvasi™ before December 18, 2018. Amgen later served notice that it would not commence commercial marketing…
2Cases cited6 opinions
- Maryland Casualty Co. v. Pacific Coal & Oil Co.Supreme Court of the United States · 1941
- Lincoln Benefit Life Co. v. AEI Life, LLCCourt of Appeals for the Third Circuit · 2015
- Gould Electronics Inc., F/k/a Gould Inc. American Premier Underwriters, Inc. v. United States of America Gould Electronics Inc. American Premier Underwriters, Inc.Court of Appeals for the Third Circuit · 2000
- Common Cause of Pennsylvania v. PennsylvaniaCourt of Appeals for the Third Circuit · 2009
- Sandoz Inc. v. Amgen Inc.Supreme Court of the United States · 2017
1 more not listed; retrieve them via the Exa API.
3Cited by3 opinions
- Gorton v. Air & Liquid Systems Corp.District Court, M.D. Pennsylvania · 2022
- PETERYDistrict Court, E.D. Pennsylvania · 2025
- Saydlin v. AshbyDistrict Court, M.D. Pennsylvania · 2024